New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 19, 2014
16:27 EDTITMN, LOCK, CPB, BRCM, TXN, MU, NVDA, AZN, PFE, DTV, TOn The Fly: Closing Wrap
Stocks on Wall Street were higher following a trading day marked by light volume, a quiet economic calendar and two headline making M&A announcements. The averages began the day slightly below the flat line, but within minutes the Nasdaq and S&P 500 made it into positive ground. The Dow followed by the end of the morning, but the averages moved in a narrow range from there. Despite the range-bound trading, the market internals pointed to a pretty broad based move higher, with advancers ahead of declining stocks by almost 2 to 1. ECONOMIC EVENTS: In the U.S., no major domestic economic data was reported. COMPANY NEWS: AT&T (T) shares slid 36c, or 0.98%, to $36.38 after the company confirmed over the weekend that it has agreed to acquire DirecTV (DTV) for $95.00 per share, including $28.50 per share in cash and $66.50 per share in AT&T stock. After the announcement, analysts at Raymond James upgraded AT&T to Buy from Market Perform, noting that they do not expect another buyer to emerge for DirecTV. Meanwhile, DirecTV shares were downgraded to Equal Weight from Overweight at Evercore and to Hold from Buy at Wunderlich. Shares of DirecTV fell $1.53, or 1.77%, to $84.65 after the deal, which has been widely speculated about in the media in recent weeks, was confirmed... Also over the weekend, Pfizer (PFE) raised its bid for AstraZeneca (AZN), but the U.K. drugmaker again rejected this "final" takeover proposal. Shares of Pfizer rose 16c, or 0.55%, to $29.28 after the rejection, while shares of AstraZeneca trading in New York dropped $9.64, or 12.01%, to $70.64. MAJOR MOVERS: Among the notable gainers was InterMune (ITMN), which gained $4.61, or 13.44%, to $38.92 after reporting results from a study evaluating pirfenidone and having its shares upgraded to Outperform at Leerink. Also higher was NVIDIA (NVDA), which rose 58c, or 3.23%, to $18.54 after it was one of several semiconductor stock, along with Micron (MU), Texas Instruments (TXN), and Broadcom (BRCM), that were upgraded to Outperform from Sector Perform by RBC Capital in a note to investors earlier today. Among the noteworthy losers was LifeLock (LOCK), which fell $2.28, or 17.57%, to $10.70 after disclosing that the company is going to temporarily suspend its Wallet mobile application since it is not fully compliant with applicable payment card industry security standards. Also lower were shares of Campbell Soup (CPB), which dropped $1.06, or 2.35%, to $44.06 after the company reported mixed third quarter results and lowered its fiscal 2014 outlook. INDEXES: The Dow was up 20.55, or 0.12%, to 16,511.86, the Nasdaq was up 35.23, or 0.86%, to 4,125.81, and the S&P 500 was up 7.22, or 0.38%, to 1,885.08.
News For T;DTV;PFE;AZN;NVDA;MU;TXN;BRCM;CPB;LOCK;ITMN From The Last 14 Days
Check below for free stories on T;DTV;PFE;AZN;NVDA;MU;TXN;BRCM;CPB;LOCK;ITMN the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | all recent news | >>
August 21, 2014
10:14 EDTITMNOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:54 EDTPFE, AZNPotential Pfizer, AstraZeneca deal seen around year-end, Reuters says
Investors and analysts see Pfizer (PFE) making another attempt to acquire AstraZeneca (AZN) around year-end, even though talks between the two can resume on August 26 per British takeover rules, Reuters reports. Reference Link
08:02 EDTPFEPfizer initiates U.S. EAP for palbociclib.
Pfizer announced that the company has initiated a multi-center, open-label expanded access program in the U.S. for palbociclib. Through the program, palbociclib is being made available for use in combination with letrozole for post-menopausal women with hormone receptor positive human epidermal growth factor receptor 2 negative advanced breast cancer for whom letrozole is considered appropriate therapy.
07:55 EDTPFEActavis volatility expected to move on Pfizer considering new target report
Actavis (ACT) volatility is expected to move on Pfizer (PFE) considering other overseas alternatives, Bloomberg reports. Overall option implied volatility of 27 is near its 26-week average of 31 according to Track Data, suggesting decreasing price movement.
07:47 EDTAZN, PFEPfizer looking at new targets, including Actavis, Bloomberg reports
While it weighs another attempt to acquire AstraZeneca (AZN), Pfizer is considering other overseas alternatives, including Actavis (ACT), Bloomberg reports, citing people familiar with the matter. Pfizer prefers to reach a deal with AstraZeneca, and a move on another company is unlikely "anytime soon," Bloomberg adds, citing its sources. Shares of Actavis are rising 3%, or $6.65, to $230.01 in pre-market trading, while AstraZeneca is up 2% to $72.59. Reference Link
06:12 EDTMUDRAM prices making downward correction with oversupply concerns, DigiTimes says
Subscribe for More Information
05:42 EDTAZNIllumina announces strategic partnership with AstraZeneca, Sanofi, Janssen
Illumina (ILMN) announced it has formed collaborative partnerships with leading pharmaceutical companies to develop a universal next-generation sequencing, or NGS,-based oncology test system. The system will be used for clinical trials of targeted cancer therapies with a goal of developing and commercializing a multi-gene panel for therapeutic selection, resulting in a more comprehensive tool for precision medicine. Initial strategic partners include AstraZeneca (AZN), Janssen Biotech, a Johnson & Johnson (JNJ) company, and Sanofi (SNY). Illumina is working with the strategic partners to develop assays that detect and measure multiple variants simultaneously to support partners’ clinical trials, with the objectives of securing regulatory agency approvals and test commercialization. In parallel, Illumina is working with key thought leaders to set standards for NGS-based assays in routine clinical oncology practice, as well as to define regulatory frameworks to enable this new testing paradigm. Together, Illumina and its strategic partners aim to transition from single-analyte companion diagnostics to panel-based assays that select for “companion therapeutics.”
05:22 EDTITMNInterMune downgraded to Market Perform from Outperform at Wells Fargo
Wells Fargo downgraded InterMune to Market Perform citing valuation.
August 20, 2014
08:03 EDTPFEBristol-Myers Pfizer to present new Eliquis data
Subscribe for More Information
05:53 EDTITMNStocks with implied volatility movement; NGD ITMN
Subscribe for More Information
August 19, 2014
10:01 EDTTAT&T confirms plan to deliver U-verse with AT&T GigaPower in Jacksonville
Subscribe for More Information
07:12 EDTTFCC looks into telecom special access line rates, Reuters says
Subscribe for More Information
07:01 EDTAZNDOJ closes investigation into PLATO Brilinta clinical trial, plans no action
AstraZeneca today announced that it has received confirmation from the United States Department of Justice that it is closing its investigation into PLATO, a clinical trial with BRILINTA tablets. The government is not planning any further action. Pascal Soriot, CEO, said: “We welcome the Department of Justice’s decision not to pursue further action. We have always had absolute confidence in the integrity of the PLATO trial and we are proud of the important benefit BRILINTA offers to patients around the world suffering from acute coronary syndrome. As one of AstraZeneca’s growth platforms, we remain committed to delivering the full potential of this important medicine.” As part of our continued commitment to advancing the science behind cardiovascular medicine, AstraZeneca has initiated a clinical trial program for BRILINTA, its largest program involving more than 80,000 patients worldwide.
06:46 EDTTAT&T technology routes calls to multiple devices, Re/code says
AT&T has developed technology that sends calls from one device to many other devices, Re/code reported yesterday. Reference Link
August 18, 2014
18:33 EDTTSprint introduces Sprint Family Share Pack data plan, doubles high-speed data
Subscribe for More Information
11:41 EDTPFECubist rises after report sparks takeover interest speculation
Subscribe for More Information
09:16 EDTDTVDreamWorks Animation appoints Fazal Merchant as CFO effective September 15
Subscribe for More Information
08:47 EDTTRaymond James to hold a summit
Subscribe for More Information
08:01 EDTPFEPfizer announces submission of Palbociclib NDA to FDA
Pfizer announced it has completed the submission of a New Drug Application to the United States Food and Drug Administration for palbociclib. This NDA requests FDA approval of palbociclib, in combination with letrozole, for the treatment of postmenopausal women with estrogen receptor positive, human epidermal growth factor receptor 2 negative advanced breast cancer who have not received previous systemic treatment for their advanced disease. The submission is based on the final results of PALOMA-1, a randomized, Phase 2 trial comparing palbociclib plus letrozole versus letrozole alone in this population of patients. Palbociclib received Breakthrough Therapy designation from the FDA in April 2013, for the first-line systemic treatment of women with advanced or metastatic ER+, HER2- breast cancer. This designation was based on interim data from the PALOMA-1 trial. The FDA has a 60-day filing review period to determine whether the NDA is complete and acceptable for filing. Pfizer will communicate the Agency’s decision.
07:57 EDTAZN, PFECambridge Healthtech Institute to hold a summit
6th Annual Bioprocessing Summit to be held in Boston on August 18-22.
1 | 2 | 3 | 4 | 5 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use